Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by ClariVest Asset Management LLC

ClariVest Asset Management LLC grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 69.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,582 shares of the company’s stock after purchasing an additional 4,331 shares during the period. ClariVest Asset Management LLC’s holdings in Medpace were worth $4,358,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Rise Advisors LLC acquired a new stake in Medpace in the first quarter valued at $27,000. Mather Group LLC. acquired a new stake in shares of Medpace in the first quarter valued at about $28,000. Fidelis Capital Partners LLC purchased a new stake in Medpace during the first quarter worth about $31,000. DT Investment Partners LLC purchased a new stake in Medpace during the second quarter worth about $41,000. Finally, J.Safra Asset Management Corp grew its position in Medpace by 87.0% during the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after buying an additional 47 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on MEDP. Robert W. Baird decreased their price target on Medpace from $469.00 to $430.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 24th. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a report on Thursday, September 5th. TD Cowen cut their price target on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Mizuho assumed coverage on shares of Medpace in a research report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price objective on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Tuesday, July 23rd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $423.00.

Medpace Stock Down 3.4 %

MEDP stock opened at $327.80 on Wednesday. The stock has a market capitalization of $10.16 billion, a price-to-earnings ratio of 33.41, a price-to-earnings-growth ratio of 1.74 and a beta of 1.36. The stock’s fifty day simple moving average is $387.82 and its 200-day simple moving average is $394.55. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The business had revenue of $528.10 million for the quarter, compared to analysts’ expectations of $528.41 million. During the same period last year, the company earned $1.93 earnings per share. The company’s quarterly revenue was up 14.6% on a year-over-year basis. As a group, analysts anticipate that Medpace Holdings, Inc. will post 11.66 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.